文献速递乳腺病理细胞病理与分子病理

复发转移性乳腺癌细胞块中HER2双色原位杂交评估

HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.
PubMed 文献 · Cancer Cytopathol · 2019-09-22

该研究评估了复发或转移性乳腺癌福尔马林固定细胞块(CB)中,亮视野双色原位杂交(DISH)与免疫组化(IHC)和/或荧光原位杂交(FISH)检测HER2状态的一致性。共纳入30例细胞块,DISH与IHC和/或FISH结果100%一致(30/30)。DISH可作为反射检测与IHC联合替代FISH,在细胞块中可靠评估HER2扩增。

要点

  • 细胞块中DISH与IHC/FISH检测HER2状态100%一致。
  • DISH可替代FISH作为IHC反射检测方法。
  • 细胞块肿瘤细胞>50个时HER2检测可靠。

核心结论

  • 在复发或转移性乳腺癌福尔马林固定细胞块中,DISH与IHC和/或FISH检测HER2状态完全一致。
  • DISH可作为反射检测与IHC联合替代FISH,高效可靠地确定HER2扩增。

研究设计与样本

  • 回顾性研究,检索2010至2018年经细针穿刺或体腔积液引流诊断的乳腺癌复发或转移患者。
  • 选择福尔马林固定细胞块中肿瘤细胞>50个的病例,共30例。
  • 所有细胞块均行HER2 DISH检测,并记录原发乳腺癌HER2状态。

主要发现

  • 30例细胞块来源包括腋窝淋巴结5例、纵隔淋巴结8例、内乳淋巴结1例、锁骨上淋巴结2例、门腔淋巴结1例、胸壁3例、胸水3例、骨4例、肝2例、肺1例。
  • 所有病例在研究机构行HER2 IHC,由乳腺病理学家按ASCO/CAP指南评分。
  • HER2 DISH结果与同期IHC和/或FISH显示100%一致性(30/30例)。

关键数值与推荐

  • 细胞块肿瘤细胞>50个为纳入标准。
  • HER2 IHC按ASCO/CAP指南评分。
  • DISH与IHC和/或FISH的一致性为30/30例(100%)。

临床怎么用

  • 对复发或转移性乳腺癌的细胞块,可行HER2 DISH作为IHC反射检测,替代FISH。
  • 确保细胞块肿瘤细胞>50个以保证HER2检测准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer recurrences or metastases often are diagnosed using cytology material. Cell blocks (CBs) with adequate cellularity are crucial for the determination of accurate hormonal and human epidermal growth factor receptor 2 (HER2) status and to guide treatment. In the current study, the authors evaluated the concordance of HER2 status between bright-field dual in situ hybridization (DISH), fluorescence in situ hybridization (FISH), and HER2 immunohistochemistry (IHC) performed on formalin-fixed CBs of recurrent and metastatic breast cancers. METHODS: The authors searched for patients who had breast carcinoma recurrences or metastases diagnosed between 2010 and 2018 by fine-needle aspiration or by the drainage of body cavity fluids with HER2 IHC and/or FISH performed on formalin-fixed CBs. Cases with adequate tumor cellularity (>50 cells) were selected. HER2 DISH was performed on all CBs. HER2 status of the primary breast carcinoma was recorded. RESULTS: Formalin-fixed CBs were identified from 30 patients with breast cancer recurrences and metastases in axillary lymph nodes (LNs) (5 patients), mediastinal LNs (8 patients), internal mammary LNs (1 patient), supraclavicular LNs (2 patients), portocaval LNs (1 patient), chest wall (3 patients), pleural fluid (3 patients), bone (4 patients), liver (2 patients), and lung (1 patient). All cases had HER2 IHC performed at the study institution and were scored by breast pathologists according to the American Society of Clinical Oncology/College of American Pathologists guidelines. The HER2 DISH results demonstrated 100% concordance (30 of 30 cases) with the concurrent IHC and/or FISH. CONCLUSIONS: All methods of HER2 evaluation were found to accurately identify the amplification status. DISH can be used in tandem with IHC as a reflex assay instead of FISH and is an efficient and reliable method with which to determine HER2 amplification in formalin-fixed CBs.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Edelweiss M, Sebastiao APM, Oen H, et al. HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma. Cancer Cytopathol. 2019. PMID: 31544361. doi:10.1002/cncy.22184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。